Skip to main content
. 2021 Jul 6;12:20406207211027458. doi: 10.1177/20406207211027458

Figure 5.

Figure 5.

AEs per patient-year during combination and monotherapy phases. 43

*n = 40 includes 30 patients who completed 12 cycles of tafasitamab plus lenalidomide and continued tafasitamab monotherapy and 10 patients who discontinued lenalidomide but continued tafasitamab monotherapy.

AE, adverse event; LEN, lenalidomide.